Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of diabetic clinically significant macular edema with intravitreal ranibizumab (LUCENTIS)
2008-006879-71Phase 2Active
- Sponsor
- Providence Little Company of Mary Medical Center San Pedro
- Start
- Feb 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Providence Little Company of Mary Medical Center San Pedro. Primary endpoints: Visual acuity improvement at one year, Central macular thickness reduction at one year and 1 more. Started Feb 2009; status: active.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2008-006879-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006879-71.